The board of Neimeth International Pharmaceuticals Plc can raise an additional N30 billion from the capital market, shareholders have declared.
They gave the authorisation for this fresh capital raise at the company’s 67th Annual General Meeting (AGM) held virtually on Thursday, June 25, 2026.
This was one of the resolutions passed at the yearly shareholders’ gathering, attended by several persons, including board and management members as well as investors and others.
The approval for new capital raise is coming after the board was, on June 23, 2025, authorised to raise up to N20.0 billion. For this tranche, only N2.440 billion was raised by the organisation, leaving an untilised balance of approximately N17.560 billion.
The company has now been given the authority to get fresh N30.0 billion, according to disclosure from Neimeth.
In the notice to the Nigerian Exchange (NGX) Limited, Neimeth said the board was asked to “raise additional capital of up to N30.0 billion through an issuance of shares (to be issued, whether by way of public offering, rights issue, private/special placement to strategic or identified investors), commercial papers, bonds, convertible and non-convertible securities), medium term notes and/or any other instruments, either as a stand-alone or by way of programmes, in such tranches, series or proportions, at such coupon or interest rates, within such maturity periods, or on such terms and conditions, through a combination of methods or processes, all of which shall be based on terms and conditions to be determined by the board and subject to obtaining the approvals of the relevant regulatory authorities.”
The shareholders resolved that “the aggregate shareholders’ approval for capital raising shall accordingly be N50.0 billion, of which approximately N2.440 billion has already been raised by way of rights issue, leaving an unutilised balance of approximately N47.560 billion available for raising.”